Showing 2871-2880 of 4166 results for "".
- AGTC Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trialhttps://modernod.com/news/agtc-provides-trial-design-update-for-its-phase-2-3-xlrp-clinical-trial/2478261/Applied Genetic Technologies Corporation provided additional information about the proposed design of the planned phase 2/3 trial for its X-linked retinitis pigmentosa (XLRP) clinical program, which is expected to commence in the first quarter of 2021, and new preliminary data on
- AGTC Announces Publication of Preclinical Data that Support the Ongoing Clinical Development of Its XLRP Gene Therapy Programhttps://modernod.com/news/agtc-announces-publication-of-preclinical-data-that-support-the-ongoing-clinical-development-of-its-xlrp-gene-therapy-program/2478200/Applied Genetic Technologies Corporation (AGTC) announced that preclinical data validating the transgene (hRPGRco) that is being evaluated in the company’s ongoing phase 1/2 clinical trial in patients with X-lined retinitis pigmentosa (XLRP) have been published in the July 15, 2020 print issue of
- Trefoil Therapeutics Begins First Clinical Trial of Regenerative Treatment for Patients with Corneal Endothelial Dystrophieshttps://modernod.com/news/trefoil-therapeutics-begins-first-clinical-trial-of-regenerative-treatment-for-patients-with-corneal-endothelial-dystrophies/2478175/Trefoil Therapeutics announced it has initiated the first clinical trial of its engineered Fibroblast Growth Factor-1 TTHX1114 for the regenerative treatment of people with corneal endothelial dystrophies (CED), including Fuchs Endothelial Corneal Dystrophy. The phase 1/2 trial (INTREPID)
- MeiraGTx Announces Positive Clinical Data of Investigational Gene Therapy for X-Linked Retinitis Pigmentosahttps://modernod.com/news/meiragtx-announces-positive-clinical-data-of-investigational-gene-therapy-for-x-linked-retinitis-pigmentosa/2478062/MeiraGTx Holdings announced 6-month data from the ongoing phase 1/2 clinical trial of AAV-RPGR, an investigational gene therapy in development for the treatment of patients with X-linked retinitis pigmentosa (XLRP) with genetically confirmed variants in the RPGR gene. Significant improve
- AGTC Announces Updated Development Plan for its X-Linked Retinitis Pigmentosa Clinical Programhttps://modernod.com/news/agtc-announces-updated-development-plan-for-its-x-linked-retinitis-pigmentosa-clinical-program/2478058/Applied Genetic Technologies Corporation announced next steps in the clinical development of the company’s potential treatment of X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene following receipt of written feedback from the FDA. The revised development p
- Samsung Bioepis Initiates Phase 3 Clinical Trial for SB15, Proposed Biosimilar to Eylea (Aflibercept)https://modernod.com/news/samsung-bioepis-initiates-phase-3-clinical-trial-for-sb15-proposed-biosimilar-to-eylea-aflibercept/2477950/Samsung Bioepis announced the initiation of phase 3 clinical trial for SB15, the company’s proposed biosimilar referencing Eylea (aflibercept). The trial is a randomized, double-masked, parallel group, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity b
- Lineage Cell Therapeutics Reinitiates Patient Enrollment in Clinical Study of OpRegen for the Treatment of Dry AMD With GAhttps://modernod.com/news/lineage-cell-therapeutics-reinitiates-patient-enrollment-in-clinical-study-of-opregen-for-the-treatment-of-dry-amd-with-geographic-atrophy/2477911/Lineage Cell Therapeutics announced that it has restarted patient enrollment in a phase 1/2a clinical study of its lead product candidate, OpRegen, a retinal pigment epithelium (RPE) cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD),
- Bionic Sight Doses First Patient in a Phase 1/2 Clinical Trial of a New Investigational Treatment for Retinitis Pigmentosahttps://modernod.com/news/bionic-sight-llc-doses-first-patient-in-a-phase-1-2-clinical-trial-of-a-new-investigational-treatment-for-blindness-caused-by-retinitis-pigmentosa/2477902/Bionic Sight announced that it has dosed the first patient in the company’s phase 1/2 clinical trial of BS01, an optogenetic gene therapy for patients with retinitis pigmentosa. This is an important step toward bringing BS01 forward as a treatment to enable patients with retinal degenerative dise
- New Paper in Clinical and Experimental Optometry Summarizes SARS-CoV-2 Interaction With the Ocular Surfacehttps://modernod.com/news/new-paper-in-clinical-and-experimental-optometry-summarizes-sars-cov-2-interaction-with-the-ocular-surface/2477800/“The ocular surface, coronaviruses and COVID-19,” an extensive literature review now published in Clinical and Experimental Optometry, considers a number of questions regarding SARS-CoV-2 transmission and the ocular surface. In a complex and fast-moving subject area, the paper provides a
- FDA Gives Octapharma USA Green Light to Conduct Phase 3 Clinical Trial of COVID-19 Treatmenthttps://modernod.com/news/fda-gives-octapharma-usa-green-light-to-conduct-phase-3-clinical-trial-of-covid-19-treatment/2477798/The FDA has approved the investigational new drug application submitted by Octapharma USA for a phase three clinical trial on the efficacy and safety of Octagam 10% [Immune Globulin Intravenous (Human)] therapy in COVID-19 patients with severe disease progression. The primary objective of